ISSUER INFORMATION AND DISCLOSURE STATEMENT

PURSUANT TO RULE

15c2-11(a)(5)

November 11, 2016

Groupe Athena, Inc.
10/234 Dadisheth Agiary Lane
Kalbadevi, Mumbai 400002
Maharashtra, India
PHONE: (877) 647-6876

The company has a corporate website at www.groupeathena.com. The reference to this website does not constitute incorporation by reference of the information contained therein.

Federal ID No.	CUSIP No.
27-1794631	399454107

ISSUER'S EQUITY SECURITIES

COMMON STOCK

$0.01 Par Value

100,000,000 Common Shares Authorized

47,136,900 Issued and Outstanding

Groupe Athena Inc. is responsible for the content of this Information and Disclosure Statement. The information contained in this report has not been filed with or approved by the Securities and Exchange Commission, any state securities commission, the National Association of Securities Dealers, or any other regulatory body. This document contains forward-looking statements. Forward-looking statements do not represent historical facts, but rather statements about management's beliefs, plans and objectives about the future, as well as assumptions and judgments concerning such beliefs, plans, and objectives. The statements are evidenced by terms such as "anticipate," "estimate," 'should," "expect," "believe," "intend," and similar expressions. Although these statements reflect management's good faith beliefs and projections, they are not guarantees of future performance and they may not prove true. These projections involve risk and uncertainties that could cause the Company's actual results to differ materially from those addressed in the forward-looking statements. These risks and uncertainties include, but are not limited to, changes in general economic, market, or business conditions; changes in laws or regulations or policies of federal and state regulators and agencies; and other circumstances beyond the Company's control. Consequently all of the forward-looking statements made in this document are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated will be realized, or if substantially realized, will have the expected consequences on the Company's business or operations.

GROUPE ATHENA INC.

INFORMATION AND QUARTERLY UPDATE DISCLOSURE STATEMENT

November 11, 2016

ITEM 1: Name of Issuer: Groupe Athena Inc.

ITEM 2: Address

10/234 Dadisheth Agiary Lane
Kalbadevi, Mumbai 400019
Maharashtra, India
Tel: (877) 647-6876
Website: www.groupeathena.com
Email: info@groupeathena.com

ITEM 3: Security Information:

Trading Symbol: **GATA**
Exact Title & Class of Securities Outstanding: **Common Equity Shares - 47,136,900 shares**
CUSIP**: 399454107**
Par or stated value: **$0.01**
Total shares Authorized: **100,000,000 shares as of Sept 30, 2016**
Total shares outstanding**: 47,136.900 shares as of Sept 30, 2016**

Period End Date	# of Shares Authorized	# of Shares Outstanding	Freely Tradable Shares
Sept 30, 2016	100,000,000	47,136,900	7,345,450
June 30, 2016	100,000,000	47,136,900	7,345,450
June 30, 2015	100,000,000	47,136,900	6,260,450
June 30, 2014	100,000,000	47,136,900	4,865,450
June 30, 2013	100,000,000	47,136,900	4,091,600
June 30, 2012	100,000,000	47,136,900	2,621,600
June 30, 2011	100,000,000	47,136,900	2,171,600
June 30, 2010	100,000,000	47,136,900	2,070,000

** The company announced a 20:1 split of common shares on July 1, 2009.

ITEM 3A: Transfer Agent:

Globex Transfer LLC
280 Deltona Boulevard, Suite 202
Deltona, FL 32725
Tel: (813) 344-4490

Is the Transfer Agent Registered under the Exchange Act: **YES**

RESTICTIONS ON TRANSFER OF SECURITY:

The company has a total of **47,136,900** shares outstanding as of September 30, 2016 of which **7,345,450** shares are freely transferable. The balance of the 39,791,450 shares is restricted and may be transferred only as per Rule 144 of the Securities Exchange Act (1934).

TRADING SUSPENSION ORDERS ISSUED BY THE SEC IN THE PAST 12 MONTHS:

None

ITEM 4: Issuance History:

There have been no changes in total shares outstanding by the issuer in the past 2 fiscal years and any interim period thereafter. The company has not issued any shares during the past two years and shares outstanding remain the same since July 1, 2009.

ITEM 5: Financial Statements:

The unaudited financial statements of the issuer as of September 30, 2016 are attached to the end of this Annual Update, and the financial statements included therein, and where they are located, are as follows:

Statement of Operations	Page 9
Balance Sheet	Page 10
Cash Flow Statement	Page 11
Statement of Changes to Shareholder Equity	Page 12
Notes to Financial Statements	Page 13

ITEM 6: Issuer's Business, Products & Facilities

A: Description of Issuer's Business Operations:

Serving India and South East Asia, Groupe Athena has been serving companies abroad in obtaining FDA approval for pharmaceuticals, medical products and devices for export to America. The goal is to ensure each of our clients passes FDA inspection by assisting them from concept through development, with consultation through all the regulatory requirements, filings, and processes to achieve FDA compliance and approval. Net revenues for the quarter ended September 30, 2016 were $17,364,713 and net loss was $905,607.

B: Date & State of Incorporation

Groupe Athena, Inc was originally incorporated in the State of New Jersey in June 2008.

C: Issuer's Primary SIC Code:

The Issuer's primary SIC Code is 8999.

D: Issuer's Fiscal Year & Date:

The fiscal year end date is June 30.

E: Principal Products or Services and their markets:

Groupe Athena, Inc. presently offers the following services:

- Analytical QC
- QA Functions
- Readiness for Inspections
- Compliance
- Validation
- Clinical Trial Management
- Regulatory/Legal
- Preparation of Regulatory Filings (IND's/PMA's/NDA's/ANDA's/510Ks etc)
- Compliance Assessments (GLP, GMP, GXP)
- Risk Assessments
- Mock FDA Audits

- Medical Device Support
- CMC Support
- GMP Training
- Facility Layout Consulting
- Utilities, Process, IT, Computer, and Cleaning Validation
- Training

All of the services are provided from the facilities located in Mumbai, India and the clients are various pharmaceutical companies based in India.

ITEM 7: Issuer's Facilities

The Issuer leases a 35,000 square foot industrial building located in Mumbai, India. The facility is equipped with state of the art laboratory and testing equipment predominately used for the services rendered but also includes four executive offices and an administrative office for accounting, customer service and sales functions.

In April 2012, the company acquired a 37,500 square foot facility in Nashik District, Maharashtra at a total cost of $1.68 million. The facility is approximately 85 miles from the corporate offices in Mumbai and is an existing industrial facility. The company has been attempting to get all the approvals in place for this project and though this process was expected to be completed by April, 2013 it has been delayed. Considering the current business and political climate in India, the management has decided to shelve this project for the time being and has decided to put the site up for sale.

Management's Discussion and Analysis or Plan of Operation

During the quarter, revenues dipped 23.5% due to completion of a major contract which had been on for more than 5 years. However, despite this, net income without considering the research expense write off was $1.874 million as compared to $599,441 in the corresponding quarter of the previous year, mainly due to improving margins. The company wrote off $2.78 million as research and development expenses in keeping with established accounting policies, due to which the company posted its first net loss of $905,607.

However, due to the fact that one more major contract is slated for completion later in the fiscal year, management estimates that current year revenues would be in the range of $50 million.

Management has initiated aggressive marketing measures to get large long term contracts to reverse the trend of falling revenues and the company expects to bounce back in the next fiscal. The Indian industry is currently focusing on exports to the USA and a lot of companies are looking to get their products approved by the FDA for US sales. All these are potential clients and our Company has an advantage that due to the facilities being based in India, we are able to deliver quick feedback to our clients and there is a degree of comfort resulting in order generation.

The company has decided to temporarily suspend it's development of "Atorvastatin", a cholesterol lowering drug due to the uncertainty caused by the "Brexit" referendum. The company will take a decision on restarting research when the situation becomes clearer. The research and development write-off in the current quarter reflects this position of the company.

ITEM 8A: Names of Officers, Directors and Control Persons

The following list sets forth the name, address, and position of each executive officer and director of the Issuer as of the date hereof:

Name	Position	Shares	%
Dipika Purohit 111 Remsen Avenue Avenel, NJ 07001	CEO	2,500,000	5.3%
Dr. Chitra Saxena 1 Fairfield Road Staines-upon-Thames, Wraysbury, TW19 5DU United Kingdom	Director	1,500,000	3.2%
Prakash Iyer 327 Makharia House Sardar V.P. Road, Khetwadi Mumbai 400004, India	Director	6,886,900	14.6%
Kalpathy Parameswaran 16 Foote Lane Morris Plains NJ 07950	Director	27,564,550	58.5%

ITEM 8B: Legal / Disciplinary History

1. **A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses).**

None

2. **The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities.**

None

3. **A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, or vacated.**

None

4. **The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities**.

None

ITEM 8C: Beneficial Shareholders

The Issuer has only one beneficial shareholder owning more than 10% of the Issuer's equity securities:

Allianz Atlantis Partners LLC
16 Foote Lane
Morris Plains, NJ 07950
Managing Member: Kalpathy Parameswaran
Equity Ownership: 27,564,550 shares (58.5%)

ITEM 9: Third Party Providers

Legal Counsel:
Mr. Anthony Sarsano
4500 Cottage Place
Union City, NJ 07087
Tel: (201) 864-5825

ITEM 10: ISSUER CERTIFICATION:

I, D. Purohit, certify that:

1. I have reviewed this quarterly disclosure statement dated November 11, 2016 of Groupe Athena Inc.,

2. Based on my knowledge, this disclosure statement does not contain any untrue statements of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which the such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure document.

Dated: November 11, 2016

Certified by: **/s/ D. Purohit**
D. Purohit, Chief Executive Officer

Groupe Athena Inc.

UNAUDITED FINANCIAL STATEMENT

QUARTER ENDED: SEPTEMBER 30, 2016

Un-audited financial statements for Groupe Athena Inc., for the period ending September 30, 2016 have been prepared by Management. Accordingly, the financial statements have not been reviewed by independent auditors and do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

Groupe Athena Inc.

Statement of Operations	July 1 to Sept 30, 2016	July 1 to Sept 30, 2015	June 30 2016	June 30 2015
Revenues	**17,364,713**	**22,672,908**	**75,914,423**	**70,867,148**
Operating Expenses				
Cost of Revenue	11,423,452	15,128,147	50,187,013	46,990,590
Sales & Marketing Expenses	2,477,579	3,013,018	10,083,734	9,475,080
General & Administrative Expenses	716,792	929,310	2,970,415	2,696,424
Research & Development Expenses	423,834	2,116,729	3,557,145	3,519,884
Total Operating Expenses	**15,041,657**	**21,187,204**	**66,798,307**	**62,681,978**
Operating Income / (Loss)	**2,323,056**	**1,485,704**	**9,116,116**	**8,185,170**
Depreciation & Amortization	90,541	772,172	1,446,510	2,708,453
Net Income / (Loss) before Income Taxes	**2,232,515**	**713,532**	**7,669,606**	**5,476,717**
Provision for Taxes	357,619	114,091	1,218,210	863,396
Research & Development Expenses Written off	2,780,503	-	-	-
Net Income /(Loss) after Income Taxes	**(905,607)**	**599,441**	**6,451,396**	**4,613,321**
Weighted Average Shares Outstanding, basic & diluted	**47,136,900**	**47,136,900**	**47,136,900**	**47,136,900**
Net Earnings per Share, basic & diluted	**(0.02)**	**0.01**	**0.14**	**0.10**

Groupe Athena Inc.

Balance Sheet	Sept 30 2016	Sept 30 2015	June 30 2016	June 30 2015
Current Assets				
Cash & Equivalents	382,651	330,178	377,389	328,548
Short Term Investments	10,735,782	9,102,013	10,187,364	9,012,259
Accounts Receivables	983,539	1,210,872	1,220,653	1,200,289
Inventories	32,004	30,823	31,972	30,286
Prepaid Expenses	871	825	864	856
Deposits	10,454,817	8,341,509	9,228,878	8,620,382
Total Current Assets	**22,589,664**	**19,016,220**	**21,047,120**	**19,192,620**
Fixed Assets				
Property, Plant & Equipments - Gross	14,793,457	13,937,487	14,367,625	13,937,487
Less: Accumulated Depreciation	(14,304,347)	(13,539,468)	(14,213,806)	(12,767,296)
Property, Plant & Equipments - Net	489,110	398,019	153,819	1,170,191
Long Term Investments	25,000	25,000	25,000	25,000
Research & Development Expenses	9,316,038	8,027,619	12,096,541	6,480,547
Total Fixed Assets	**9,830,148**	**8,450,638**	**12,275,360**	**7,675,738**
Total Assets	**32,419,812**	**27,466,858**	**33,322,480**	**26,868,358**
Current Liabilities				
Accounts Payable	3,872	3,905	3,801	3,825
Accrued Expenses	792	776	826	801
Customer Advances	58,791	52,298	55,903	53,329
Other Current Liabilities	602	472	588	437
Total Current Liabilities	**64,057**	**57,451**	**61,118**	**58,392**
Total Liabilities	**64,057**	**57,451**	**61,118**	**58,392**
Common Stock	471,369	471,369	471,369	471,369
Additional Paid In Capital	1,885,476	1,885,476	1,885,476	1,885,476
Retained Earnings / (Deficit)	29,998,910	25,052,562	30,904,517	24,453,121
Total Equity	**32,355,755**	**27,409,407**	**33,261,362**	**26,809,966**
Total Liabilities & Shareholders' Equity	**32,419,812**	**27,466,858**	**33,322,480**	**26,868,358**
Common Shares Outstanding (Nos)	**47,136,900**	**47,136,900**	**47,136,900**	**47,136,900**

Groupe Athena Inc.

Statement of Cash Flows

	Sept 30 2016	Sept 30 2015
Net Income	**(905,607)**	**599,441**
Adjustments to reconcile net income to cash provided from operations		
Accounts Receivable	237,114	(10,583)
Inventories	(32)	(537)
Prepaid Expenses	(7)	31
Accounts Payable	71	80
Accrued Expenses	(34)	(25)
Customer Advances	2,888	(1,031)
Other Current Liabilities	14	35
Net Cash Provided by Operating Activities	**(665,593)**	**587,411**
Investing Activities		
Machinery & Equipment	(425,832)	-
Depreciation	90,541	772,172
Research & Development Expenses	2,780,503	(1,547,072)
Short Term Investments	(548,418)	(89,754)
Deposits	(1,225,939)	278,873
Net Cash Provided by Investing Activities	**670,855**	**(585,781)**
Financing Activities		
Short Term Debt	-	-
Common Stock	-	-
Net Cash Provided by Financing Activities	**-**	**-**
Net Cash Increase for the period	**5,262**	**1,630**
Cash at Beginning of period (June 30)	**377,389**	**328,548**
Cash at end of period	**382,651**	**330,178**

Groupe Athena, Inc.

Statements of Changes to Shareholder Equity

	Amount ($)
Balance as at June 30, 2016	33,261,362
Net Income	(905,607)
Ending Balance as at September 30, 2016	**32,355,755**

Groupe Athena Inc.

Notes to Financial Statements

NOTE A - ORGANIZATION AND NATURE OF ACTIVITIES

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1, 2008. Groupe Athena Inc. (the "Company") is a research and testing organization and helps various pharmaceutical companies in India to get regulatory approvals and facilitate exports of pharmaceuticals to the United States.

The company has a research and marketing facility in India, employing 22 consultants and marketing personnel. The company is working towards aggressively expanding it's presence in the Indian pharmaceutical industry and has various contracts on hand currently.

The Company is currently engaged in and devotes considerable time to financial planning, recruiting and training sales personnel and establishing a market presence for its services. Though revenues are increasing at a brisk pace, the management believes that a significant market presence and sales account base has yet to be achieved.

The board of directors has the authority, without action by the Company's stockholders, to provide for the issuance of preferred stock in one or more classes or series and to designate the rights, preferences and privileges of each class or series, which may be greater than the rights of the common stock.

NOTE B -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company has prepared the financial statements in accordance with the International Financial Reporting Standards (IFRS). **The company has changed it's accounting method from GAAP to IFRS in June 2012 and has restated it's accounts for the years ending 2009, 2010, 2011 & 2012.**

Cash, Equivalents & Short Term Investments

These assets consist of highly liquid investments, which are readily convertible into cash and have maturities of three months or less. The Company places its temporary cash investments with financial institutions and limits the amount of credit exposure to any one financial institution. Interest Income for the quarter ending September 30, 2016 was $15,762 and has been included in revenues.

Accounts Receivable

Allowance for Doubtful Accounts --The Company maintains reserves on customer accounts where estimated losses may result from the inability of its customers to make required payments. These reserves are determined based on a number of factors, including the current financial condition of specific customers, the age of accounts receivable balances and historical loss rate.

Inventory

Inventories are stated at the lower of cost or market, cost being determined under the first-in, first-out method. The Company periodically reviews inventories and items considered outdated or obsolete are reduced to their estimated net realizable value.

Share capital

On July 1, 2009 the company announced a forward split of 20 shares for every share held. This increased the number of shares outstanding from 2,356.845 shares to 47,136,900 shares outstanding.

The management is pleased to announce that the company has complied with all the requirements of the various regulatory agencies and the shares of the company were listed on pinksheets.com in April, 2010. The ticker symbol of the company is "GATA". On April 4, 2011 the company got eligibility from the Depository Trust Company to allow electronic quotes and trading.

Machinery and Equipment

Machinery and equipment is stated at cost, net of accumulated depreciation and amortization, which is computed using the straight-line method over the estimated useful lives of the related assets of three to five years. Expenditures for maintenance and repairs are charged to expense as incurred. Major improvements that extend the lives of assets are capitalized. Any gain or loss on disposition of assets is recognized currently. Accumulated Depreciation was $14,304,347 as at September 30, 2016.

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairments whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the asset exceeds the fair value. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Research & Development Expenses

Research costs, other than capital expenditures, are charged to operations as incurred. Expenditures on products developed internally are capitalized if it can be demonstrated that:

- it is technically feasible to develop the product for it to be sold;
- adequate resources are available to complete the development;
- there is an intention to complete and sell the product;
- the company is able to sell the product;
- sale of the product will generate future economic benefits' and
- expenditure on the project can be measured reliably.

Development expenses are charged to operations as incurred unless such costs meet the criteria for deferral and amortization. No development costs have been deferred to-date.

Income Taxes

The Company accounts for income taxes in accordance with the provisions of the IFRS. Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax basis of assets and liabilities and their reported amounts using enacted rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Revenue Recognition

The Company sells its services to pharmaceutical manufacturers. The Company recognizes revenue when the evidence of an arrangement exists, pricing is fixed and determinable, collection is reasonably assured, and the rendering of the services has commenced. Payment is due as per the contracts the company has entered into and no service is rendered until the client has given an advance.

Deferred Financing Costs

Costs incurred to obtain financing have been written off as expenses in the year they were incurred.

Advertising

Advertising costs are charged to expense as incurred, and are included in selling and marketing expenses. Advertising expense for the quarter ending September 30, 2016 was $372,542.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted by the IFRS requires management to make estimates and assumptions that affect the amounts reported in its financial statements and accompanying notes. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued liabilities and loans and notes payable. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments. The estimated fair value is not necessarily indicative of the amounts the Company would realize in a current market exchange or from future earnings or cash flows.

Compensated Absences

The Company does not accrue for compensated absences and recognizes the costs of compensated absences when paid to employees. Accordingly, no liability for such absences has been recorded in the accompanying consolidated financial statements. Management believes the effect of this policy is not material to the accompanying financial statements.

NOTE C - INVENTORY
The components of inventory as of September 30, 2016

Supplies & Consumables	$32,004

NOTE D – SHORT TERM DEBT

As of September 30, 2016 the company had no debt outstanding.

NOTE E- COMMITMENTS AND CONTINGENCIES
Operating Lease Commitments
The Company leases office space under operating leases expiring at various dates through 2018. In the normal course of business, operating leases are generally renewed or replaced by other leases. Rent expense for the quarter ending September 30, 2016 was $64,015.

CERTIFICATION
I, D. Purohit, Chairman of the Board and President of Groupe Athena Inc., hereby certify that the financial statements filed herewith and the attached notes, fairly present, in all material respects, the financial position as of September 30, 2016 and the results of operations and cash flows for the period ending September 30, 2016 in conformity with accounting principles generally accepted by the IFRS, as consistently applied.
Dated this 11th day of November, 2016.

_____-sd-_____
D. Purohit,
CEO